Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
about
Neurobiology of opioid dependence in creating addiction vulnerabilityProtocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United StatesMedication Overuse in Chronic Pain.Secular trends in opioid prescribing in the USA.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.The societal cost of heroin use disorder in the United States.Tamper-resistant drugs cannot solve the opioid crisisNationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions.Epidemiological evidence on extra-medical use of prescription pain relievers: transitions from newly incident use to dependence among 12-21 year olds in the United States using meta-analysis, 2002-13Specific behavioral and cellular adaptations induced by chronic morphine are reduced by dietary omega-3 polyunsaturated fatty acids.Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study.Safety Issues Regarding Prescription Opioids.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodonePrevention of Opioid Misuse: A Summary with Suggestions from a Pain Working Group.No End in Sight: The Abuse of Prescription Narcotics.Type of opioid dependence among patients seeking opioid substitution treatment: are there differences in background and severity of problems?The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.Heroin use onset among nonmedical prescription opioid users in the club scene.Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Drug Formulation Advances in Extended-Release Medications for Pain Control.Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.Discordant reporting of nonmedical opioid use in a nationally representative sample of US high school seniors.Opiate Injection-associated Infective Endocarditis in the Southeastern United States.An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program.Patterns of Opioid Prescribing for an Orthopaedic Trauma Population.The consequences of drug misuse on post-marketing surveillance.Facing the challenge of pain management and opioid misuse, abuse and opioid-related fatalities.Drug use generations and patterns of injection drug use: Birth cohort differences among people who inject drugs in Los Angeles and San Francisco, California.Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain.Comments and Suggestions from Pain Specialists Regarding the CDC's Proposed Opioid Guidelines.Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers.'Delisting' OxyContin® to reduce prescription opioid-related harms in Ontario (Canada)-gauging effects 5 years later.Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis.Abuse-deterrent opioids: an update on current approaches and considerations.Mortality Quadrupled Among Opioid-Driven Hospitalizations, Notably Within Lower-Income And Disabled White Populations.Medications for substance use disorders (SUD): emerging approaches.
P2860
Q26742048-683B2BF5-55CA-4A52-84D5-5D249EBBAEF4Q27318074-55857FD6-0C9D-4054-8554-EB147B0FD041Q28554893-8B71EAE8-806C-40C0-822B-763D0C412B37Q30238960-D6478EFF-047C-49C2-ACEB-3C43507D21E4Q30839446-45F7969C-E8FF-46FA-8703-877115B474EFQ33685208-5A7BDBA4-DCCB-4F60-AF4D-5245DDDF47C6Q33739154-CA40A194-A1CB-4181-988F-8FDD58F0B2A0Q35847040-6F37D732-6A1E-441D-9C23-DDABCDFD984AQ36011523-44028A90-D44E-46EB-8635-CF74D758DBABQ36326682-3F867C19-FBFA-4A43-9AF4-DE59B96176D4Q36336144-DA317D71-5DE1-4203-A381-B7733798BF67Q36619410-B231804D-2BB2-4CDD-A40A-3D179EB93C4DQ36660835-BAE3C76E-0828-47AE-BBDC-F9CAA204DD53Q36972164-7307F45E-7DC6-4396-BCEF-4F99DC55DF10Q36996805-F82E1234-5A7F-4677-B75D-D5F8641A5C71Q37035647-115EDFDC-8493-4EBE-BAA8-557739F8B675Q37084705-CAADEAB2-FDA9-4873-A52E-9F22366EE680Q37404465-45345315-0FBC-47A9-A3E6-7F933A7260E8Q38632934-C99AA364-8791-4431-A7DE-3EB12A9CC79EQ38643889-99F0ECB2-1BF6-4A5F-A443-29F105F3FC6BQ38707436-B03E52E9-A545-4136-937C-A1A52EE2F35DQ38799636-26081AB3-CB05-4F6E-845A-E65B2ADACA07Q38809652-681BBEFF-CCB5-43B5-B095-1735D717CB7EQ38851461-CF289008-38EF-48FF-8E9C-894112F8746EQ38851643-05A56B70-F243-49F0-83EC-D78F7DBE5EE5Q39028794-F503AE8D-95AD-46BF-AD5A-5D6095EA5BD1Q39041424-E839DC90-0D9E-439A-AA5C-7124A263BE2DQ39326661-6D1AA2BA-7E83-408D-A3E1-F993AF909CB7Q39838315-85D32C77-2999-4531-A78E-293104B52027Q39954593-2C2CCBD8-6D97-43D9-91E3-3D899D912BCFQ40464430-D6E0DDDB-1BE1-422C-9DD5-5EE809054515Q42067527-3EF5E0C6-7FC1-4504-8254-D7F1A0AA5128Q43576588-3263EAB2-833E-4D47-9524-F4160B5ACB2CQ44339897-BB78BA76-6160-4090-8D36-FD10E6740E55Q44347129-72BB47C0-4A48-40BE-86EA-7F073F40BE12Q44349641-B6EB0E55-4111-4056-8012-1EF0207805CBQ44351334-9097E98D-7EDC-4F00-8F7B-304E972FD45CQ47274936-AD9BF8F1-F007-4F95-A0A4-E61BDFB1F74EQ47376047-DE6F20DE-BE1F-42F9-B8B2-6A31FE85D58BQ47731975-0BDE4B80-0AA1-4F6E-9776-A15F4530F525
P2860
Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Abuse-Deterrent Formulations a ...... essons Learned From OxyContin.
@en
type
label
Abuse-Deterrent Formulations a ...... essons Learned From OxyContin.
@en
prefLabel
Abuse-Deterrent Formulations a ...... essons Learned From OxyContin.
@en
P1433
P1476
Abuse-Deterrent Formulations a ...... essons Learned From OxyContin.
@en
P2093
Matthew S Ellis
Theodore J Cicero
P304
P356
10.1001/JAMAPSYCHIATRY.2014.3043
P407
P577
2015-05-01T00:00:00Z